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Abstract
Lung cancer carries a poor prognosis and is the most common cause of cancer-related death 
worldwide. The integrin α6β4, a laminin receptor, promotes carcinoma progression in part by 
cooperating with various growth factor receptors to facilitate invasion and metastasis. In 
carcinoma cells with mutant TP53, the integrin α6β4 promotes cell survival. TP53 mutations and 
integrin α6β4 overexpression co-occur in many aggressive malignancies. Due to the high 
frequency of TP53 mutations in lung squamous cell carcinoma (SCC), we sought to investigate the 
association of integrin β4 expression with clinicopathologic features and survival in non-small cell 
lung cancer (NSCLC). We constructed a lung cancer tissue microarray and stained sections for 
integrin β4 subunit expression using immunohistochemistry. We found that integrin β4 expression 
is elevated in SCC compared to adenocarcinoma (P<0.0001), which was confirmed in external 
gene expression datasets (P<0.0001). We also determined that integrin β4 overexpression 
associates with the presence of venous invasion (P=0.0048), and with reduced overall patient 
survival (Hazard ratio 1.46, 95% confidence interval 1.01 to 2.09, P=0.0422). Elevated integrin β4 
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expression was also shown to associate with reduced overall survival in lung cancer gene 
expression datasets (Hazard ratio 1.49, 95% confidence interval 1.31 to 1.69, P<0.0001). Using 
cBioPortal, we generated a network map demonstrating the 50 most highly altered genes 
neighboring ITGB4 in SCC which included laminins, collagens, CD151, genes in the EGFR and 
PI3K pathways, and other known signaling partners. In conclusion, we demonstrate that integrin 
β4 is overexpressed in NSCLC where it is an adverse prognostic marker.
Keywords
Integrin signaling; cell adhesion; NSCLC; pulmonary adenocarcinoma; CD44
 Introduction
Lung cancer is the leading cause of cancer-related death in the United States, with an 
estimated 158,040 deaths expected for the year 2015 [1]. Patients diagnosed with lung 
cancer have poor outcomes, with less than 17% of patients surviving 5 years [1]. Non-small 
cell lung cancer (NSCLC) is the most common form of lung cancer and can be further 
subdivided into a variety of histologic subtypes. These subtypes include adenocarcinoma 
(ADC), squamous cell carcinoma (SCC) and large cell carcinoma. Lung SCC carries a poor 
prognosis and is typically treated with surgical resection, radiation and traditional cytotoxic 
chemotherapy. While a number of targeted therapies have recently been developed for the 
treatment of NSCLC, these agents target genomic alterations that occur more frequently in 
lung ADC, such as mutations in EGFR and rearrangements of ALK and ROS1 [2, 3]. SCC 
remains difficult to treat in part due to a lack of targeted therapies and because of its 
propensity for aggressive behavior.
The integrin α6β4 is an extracellular matrix receptor that has been implicated in carcinoma 
progression [4, 5]. In normal epithelia, integrin α6β4 is expressed in the basal layer of cells 
where it binds to laminins in the extracellular matrix to nucleate the formation of stable 
adhesive structures termed hemidesmosomes [6]. In addition to serving an adhesive 
function, integrin α6β4 signaling is involved in many cellular processes including 
proliferation, survival, and wound healing [7–9]. The integrin β4 subunit (referred to herein 
as integrin β4) is particularly notable due to its long cytoplasmic signaling domain which 
contributes to its ability to promote invasive and metastatic behavior in cancer cells [5]. 
During carcinoma progression, the integrin α6β4 is released from hemidesmosomes which 
allows it to associate with the actin cytoskeleton [10]. Here, it activates RhoA, leading to 
membrane ruffling, lamellae formation and the generation of traction forces [11]. These 
processes enable cell migration, thus allowing the cell to invade and metastasize [12]. In 
addition to its effects on cell motility, the integrin α6β4 cooperates with numerous growth 
factor receptors including EGFR, ErbB-2, ErbB-3 and c-Met to amplify downstream 
signaling to pathways such as PI3K, AKT, and MAPK (for review, see [5]). The integrin 
α6β4 is overexpressed in a wide variety of human cancers, where in many documented cases 
it positively associates with poor prognosis [5].
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In carcinoma cells with mutant TP53, the integrin β4 promotes cell survival [7]. 
Interestingly, TP53 mutations and integrin β4 overexpression co-occur in many aggressive 
malignancies including basal-like breast cancer, serous ovarian carcinoma, and pancreatic 
ductal adenocarcinoma. Given that lung SCC has a high frequency of TP53 mutations, we 
predicted that integrin β4 expression in this tumor type would associate with aggressive 
behavior and poor prognosis. While integrin β4 expression in lung carcinomas has been 
studied previously, an association has not been demonstrated between integrin β4 
overexpression and clinical outcomes [13–16]. We therefore investigated integrin β4 
expression as it relates to histologic subtype, clinicopathologic features and survival in 
NSCLC. Here, we report that integrin β4 expression is elevated in lung SCC, and that its 
overexpression is associated with venous invasion and decreased overall survival in patients 
with NSCLC.
 Materials and Methods
 Lung cancer tissue microarray (TMA) construction
This project was approved by the University of Kentucky Institutional Review Board 
(13-0692-P6H). Surgically resected NSCLC cases were identified using natural language 
searches in CoPath (Cerner Corporation, Kansas City, MO). After review, a total of 216 
cases were selected for inclusion in the TMAs. These represented an assortment of 
histologic subtypes, including 83 ADCs, 102 SCCs, 12 adenosquamous carcinomas, 12 
poorly differentiated carcinomas, 2 large cell neuroendocrine carcinomas, 1 giant cell 
carcinoma, 1 pleomorphic carcinoma, 2 tumors with mixed histology (mixed ADC and large 
cell neuroendocrine) and 1 sarcomatoid carcinoma. Prior to selection for the TMA, each 
case was reviewed by a board-certified pathologist and clinicopathologic features (tumor 
grade, tumor size, histologic type, pTNM staging, presence of lymphovascular, venous, and 
pleural invasion) were recorded using cancer templates. Only primary lung cancers were 
included, and cases were excluded if there was inadequate pathologic material available. 
Original hematoxylin and eosin (H&E) stained slides were reviewed and appropriate tumor 
blocks were selected from each case. Fresh H&E stained sections were then cut from each 
selected tumor block and then reviewed by the team pathologist to identify tumor areas for 
inclusion in the TMA. Pathologic features were abstracted from pathology records and 
cancer templates using Cerner CoPath Plus v2013.01.1.070 (Cerner Corporation, Kansas 
City MO). Outcome data were collected by the Cancer Research Informatics Shared 
Resource Facility. Samples were randomly sorted by stage for allocation into the recipient 
TMA by the MCC Biostatistics and Bioinformatics Shared Resource Facility, and TMAs 
were constructed by the MCC Biospecimen and Tissue Procurement Shared Resource 
Facility. Three 2 mm diameter tissue cores were obtained from each tumor specimen, which 
were then transferred to recipient paraffin blocks (12 blocks) using a TMArrayer (Pathology 
Devices, Westminster, MD). Sections used for integrin β4 immunohistochemistry had 
interpretable tissue cores in 211/216 cases. Patient characteristics for these 211 cases are 
summarized in Table 1.
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TMA sections (4 µm) were stained using a rat monoclonal primary antibody to the integrin 
β4 subunit (CD 104) (clone 439-9B; BD Pharmingen, San Jose, CA) at a concentration of 
1:200 according to a previously described protocol [17]. Integrin β4 expression was scored 
by a pathologist using a semiquantitative scale as follows: negative (0), weak (1), moderate 
(2), and strong (3). Scoring was performed while blinded to clinical variables and outcome. 
Results from each of the three tissue cores were averaged to produce a final score for each 
patient.
 Data Mining
Multiple lung cancer gene expression datasets were analyzed for ITGB4 mRNA expression. 
The first of these was a NSCLC dataset generated by the Cancer Genome Atlas Research 
Network (TCGA, http://cancergenome.nih.gov/) containing 155 SCC samples and 32 ADC 
samples that were analyzed using a custom Agilent microarray. The second was a dataset 
generated by Hou et al. containing 91 NSCLCs and 65 adjacent normal lung samples that 
had been analyzed using a Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, 
CA) [18]. These datasets were viewed and downloaded using The Oncomine™ Platform 
v4.5 (Life Technologies, Ann Arbor, MI). The UCSC Cancer Browser (https://genome-
cancer.ucsc.edu/proj/site/hgHeatmap/) was used to visualize and download a processed lung 
SCC gene expression dataset (N = 155) in order to identify genes correlated with ITGB4 
[19, 20]. In addition, cBioPortal (http://www.cbioportal.org/) was used to generate a network 
map showing the 50 most highly altered genes neighboring ITGB4 in the TCGA lung SCC 
dataset [21, 22]. In order to investigate integrin β4 gene expression as it relates to patient 
survival, we analyzed a NSCLC gene expression database using the Kaplan-Meier Plotter 
[23] (N = 1,926) (http://kmplot.com/analysis/) where overall patient survival was analyzed 
using a median cutoff and the 2015 version of the database.
 Statistical Analysis
Differences between groups were analyzed using Fisher's exact test, two-tailed t-test with 
Welch’s correction, or one-way ANOVA with post hoc Tukey’s test, as appropriate. Survival 
differences were assessed via log-rank tests for univariate analyses. Significance was 
reached when P < 0.05. Statistical analyses were performed using GraphPad Prism, Version 
5.01 (Graph Pad Software, Inc. La Jolla, CA) and using the Kaplan-Meier Plotter [23].
 Results
 Integrin β4 expression is elevated in NSCLC compared to normal lung tissue
In order to examine integrin β4 expression across a large number of patient-derived samples, 
we constructed and utilized a lung cancer TMA and analyzed external gene expression 
datasets. In the Hou external dataset, NSCLCs were found to have elevated integrin β4 
expression when compared to normal lung tissue (Fig. 1A; P <0.0001), which we also 
observed in our TMA. Although normal lung tissue was not specifically selected for 
inclusion in the TMA, benign bronchial epithelium was identified adjacent to invasive 
carcinoma cells in a subset of tissue cores. As shown in Figure 1B, integrin β4 was primarily 
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expressed in basal cells and along the basement membrane of lung pseudostratified 
columnar epithelium. Weak staining was also present at the apical surface of ciliated 
columnar cells, while goblet cells and immune cells in the bronchial epithelium were 
negative for integrin β4 expression. Notably, integrin β4 expression was higher in the 
invasive carcinoma (Fig. 1C–D) than in adjacent benign bronchial epithelium. In addition, 
basal polarization of integrin β4 expression was lost in invasive carcinoma.
 Altered localization of the integrin β4 in NSCLC
Integrin β4 expression was found to be highly variable in NSCLCs with some cases 
exhibiting strong and diffuse staining, while others were completely negative for integrin β4 
expression. Staining was scored by a pathologist using a semiquantitative scale as follows: 
negative (0), weakly positive (1), moderately positive (2), and strongly positive (3) (Fig. 2A–
D). In select tumors, staining was predominantly membranous, while others exhibited a 
mixture of cytoplasmic and membranous immunoreactivity (Fig. 3A–B). Integrin β4 staining 
intensity was elevated at the tumor-stromal interface in some tumors (Fig. 3C), a 
phenomenon that has been previously described by others [14]. Individual infiltrating tumor 
cells and nests at the invasive front also tended to have elevated integrin β4 expression 
compared to cells at the center of the tumor (Fig. 3D).
 Elevated integrin β4 expression associates with venous invasion and an adverse 
prognosis in NSCLC
To decipher how integrin β4 associates with clinical features, we first compared integrin β4 
expression between histologic subtypes. Individual tissue cores from our TMA were scored 
by a pathologist and the values for each patient averaged; patients with an average integrin 
β4 IHC score of ≥ 2.5 were considered to have elevated expression. In our TMA cohort, 
integrin β4 was elevated in SCC when compared to ADC (Fig. 4A; P < 0.0001); this finding 
was confirmed in two external gene expression datasets including those from TCGA and 
from Hou et al. [18, 19] (Fig. 4B–C; P < 0.0001). Integrin β4 protein expression was also 
elevated in a subset of adenosquamous carcinomas and poorly differentiated tumors that 
were evaluated in our TMA (Table 2). Using data abstracted from pathology reports, we 
found that integrin β4 overexpression was associated with the presence of venous invasion 
(Fig. 4D–E; P = 0.0048).
To date, no data have been published that demonstrate an association between integrin β4 
expression and patient outcome in NSCLC. In our TMA cohort, integrin β4 overexpression 
(score ≥ 2.5) was significantly associated with shorter overall survival (Fig 5A; hazard ratio 
1.46, 95% confidence interval 1.01 to 2.09, P = 0.0422). This relationship was also 
significant when using a higher cutoff point (score = 3) to define integrin β4 overexpression 
(Fig. 5B; hazard ratio 1.71, 95% confidence interval 1.17 to 2.51, P = 0.0056). In addition, 
elevated integrin β4 expression was shown to associate with reduced overall survival in a 
NSCLC gene expression dataset (Fig. 5C; N = 1,926; Hazard ratio 1.49, 95% confidence 
interval 1.31 to 1.69, P<0.0001).
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 Integrin β4 associated genes
In order to explore signaling pathways and gene expression pattens that may associate with 
integrin β4 in lung cancer, cBioPortal (http://www.cbioportal.org/) was used to generate a 
list of the top 50 genes most positively correlated with ITGB4 in lung SCC. We found that 
ITGB4 was highly correlated with that of its binding partner ITGA6, as well as that of CD44 
(Fig. 6A–B; P < 0.0001), both of which are markers of cancer stem cells [24]. ITGB4 was 
also highly correlated with EGFR expression (Fig. 6C; P < 0.0001). We further generated a 
network map using cBioPortal that demonstrates highly altered genes neighboring ITGB4 
(Fig. 7). These genes included laminins (LAMA1, LAMA3, LAMB1, LAMB3, LAMC1, 
LAMC2, etc), other integrin subunits (ITGA6, ITGB1), tetraspanin CD151, genes in the 
EGFR family (EGF, EGFR, ERBB3), genes in the PI3K pathway (PIK3CA, AKT1), and 
other known signaling partners (MET, FYN).
 Discussion
In this study, we show that integrin β4 is highly expressed in lung SCC, and that its 
overexpression is associated with venous invasion and reduced overall survival in NSCLC. 
Particularly notable is the finding that integrin β4 localization is altered in invasive lung 
cancer. In benign epithelia, the integrin β4 is located at the basal aspect of cells at their 
junction with the extracellular matrix. However, during carcinoma progression, the integrin 
β4 is released from hemidesmosomes where it can accumulate at the leading edge of the cell. 
Here, the integrin associates with the actin cytoskeleton where it can then contribute to cell 
migration, thus allowing the cell to invade and metastasize. We found that in benign 
bronchial epithelium, expression of the integrin β4 is basally located; however, in invasive 
carcinoma, integrin β4 is redistributed over the cell surface, consistent with its role in 
invasion and migration. In addition, we found that integrin β4 staining is elevated at the 
invasive front of tumors and at the tumor-stromal interface. These findings underscore the 
importance of the integrin β4 in contributing to an invasive phenotype in NSCLC.
Our data support previous studies regarding integrin α6β4 and lung cancer progression. 
Early reports demonstrated that expression of the integrin α6β4 (previously described as 
TSP-180) is elevated in murine Lewis lung carcinoma variants with high metastatic potential 
[25]. Multiple studies investigating integrin β4 expression in patient-derived tissues have 
shown that it is expressed in NSCLC, with high levels observed in SCC [13–15]. A more 
recent study using gene expression profiling identified differentially expressed genes in 
samples of pulmonary ADC, SCC, and normal bronchus, where they found that integrin β4 
was significantly upregulated in SCC [16]. Notably, the integrin β4 gene (ITGB4) is 
upregulated in the basal molecular subtype of lung SCC as defined using unsupervised 
clustering of gene expression microarray data [26].
By studying external gene expression datasets, we found that expression of the integrin β4 
gene is positively correlated with expression of the cancer stem cell marker, CD44. CD44 is 
a transmembrane glycoprotein that has been shown to facilitate many aspects of tumor 
progression and is important in promoting resistance to therapy [27, 28]. Interestingly, 
integrin β4 has been implicated in promoting stem cell like properties in breast cancer [29], 
and has been identified in the cancer stem cell population in NSCLC [30]. In addition, we 
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found that expression of the integrin β4 gene is correlated with that of its binding partner, 
integrin α6 (CD49f), a known stem cell marker [31]. In the network map, integrin β4 is 
connected to a number of laminin subunits (LAMA3, LAMB3, LAMC2), which is 
consistent with the fact that integrin β4 binds laminins in the extracellular matrix. 
Interestingly, the laminins most well studied in reference to integrin α6β4 including 
laminin-1 (composed of LAMA1, LAMB1, LAMC1) and laminin-5 (which includes 
LAMA3, LAMB3, LAMC2) are most prominent. Also notable was the connection between 
integrin β4 and COL17A1, (Collagen, Type XVII, Alpha 1), as this gene encodes the BP180 
protein that is necessary for hemidesmosome assembly.
Integrin β4 cooperates with a variety of growth-factor receptors to amplify proliferative and 
invasive signaling. We found that integrin β4 gene expression was positively correlated with 
that of EGFR, and in the network map, integrin β4 was connected to genes in the EGFR 
signaling pathway. These findings are notable in light of evidence demonstrating a 
functional relationship between EGFR and integrin β4 [32, 33]. In particular, integrin β4 has 
been shown to interact with EGFR in lipid rafts where it enhances cell growth and 
proliferation [34]. Furthermore, our lab has demonstrated that in pancreatic carcinoma cells, 
integrin α6β4 promotes autocrine EGFR signaling [35].
As the integrin β4 can promote invasion, proliferation, and stem cell-like properties, it is not 
surprising that elevated integrin β4 expression is associated with poor prognosis. We found 
that elevated integrin β4 expression is a marker of poor prognosis for patients with lung 
cancer, both in our TMA cohort as well as in external gene expression datasets. These data 
are in agreement with previous studies demonstrating an association between integrin β4 
expression and poor prognosis in other cancer types [5]. In addition, we found an association 
between elevated integrin β4 expression and the presence of venous invasion. Venous 
invasion has been associated with recurrence and poor prognosis in lung and colorectal 
carcinoma [36].
In summary, we demonstrate that integrin β4 is elevated in NSCLCs compared to normal 
lung tissue, and that it is preferentially overexpressed in lung SCC. Furthermore, integrin β4 
positively associates with the presence of venous invasion and reduced survival in patients as 
evidenced from analysis of our TMA and external cohorts.
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Figure 1. Expression of integrin β4 in benign lung
In the Hou dataset, NSCLCs had greater average levels of ITGB4 mRNA than normal lung, 
P < 0.0001 via two-tailed t-test with Welch's correction (A). In benign bronchial epithelium, 
integrin β4 was expressed in basal cells and along the basement membrane, with weak 
expression at the apical surface of ciliated columnar cells (B). However, in invasive 
carcinoma, integrin β4 expression was significantly more intense in carcinoma cells than in 
adjacent benign bronchial epithelium (C, D). Magnification is 200× for all images.
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Figure 2. Integrin β4 staining intensity in NSCLC
Examples of negative (0) (A), weak (1) (B), moderate (2) (C), and strong (3) (D) integrin β4 
expression in NSCLCs. Left panels show integrin β4 staining, right show H&E. 
Magnification is 200× for all images.
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Figure 3. Localization of integrin β4 staining in NSCLC
Select NSCLC cases exhibited predominantly membranous staining (A), while others had 
strong membranous and cytoplasmic expression of the integrin β4 (B). In some cases, 
integrin β4 was elevated at the tumor-stroma interface (C), and at the invasive front of 
tumors (D). Magnification is 200× for A–C, and 100× for D.
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Figure 4. Integrin β4 expression in NSCLC by histologic subtype and association with venous 
invasion
SCCs had a higher proportion of cases with elevated integrin β4 expression than did 
adenocarcinomas, as measured using semi-quantitative IHC, P < 0.0001 via Fisher’s exact 
test (A). In the TCGA dataset, average ITGB4 mRNA expression was higher in SCCs than 
in adenocarcinomas, P < 0.0001 via two-tailed t test with Welch's correction (B). In the Hou 
dataset, average ITGB4 mRNA expression was higher in SCCs when compared to both 
normal lung tissue and adenocarcinomas, P < 0.0001 via one-way ANOVA with post hoc 
Tukey’s test (C). Integrin β4 overexpression was associated with the presence of venous 
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invasion, P = 0.0048 via Fisher’s exact test (D). An example of a tumor from the TMA with 
venous invasion, stained with H&E, integrin β4 and elastic trichrome, as noted (E). 
Magnification is 200× for all images.
Stewart et al. Page 14













Figure 5. Integrin β4 and survival in NSCLC
In our TMA cohort, elevated expression of integrin β4 was associated with shorter median 
overall survival, P = 0.0422 (A) and P = 0.0056 (B). Using the Kaplan-Meier Plotter, 
elevated integrin β4 expression was also shown to associate with reduced overall survival 
(P<0.0001) in a NSCLC gene expression database (C).
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Figure 6. ITGB4 expression correlates with ITGA6, CD44, and EGFR in SCC
By linear regression, ITGB4 mRNA expression levels positively correlated with ITGA6 (A), 
CD44 (B), and EGFR (C).
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Figure 7. Network map illustrating highly altered genes associated with ITGB4
In this network map, ITGB4 is connected to laminins (LAMA1, LAMB1, LAMC1, 
LAMA2, etc), genes in the EGFR family (EGFR, ERBB3), genes in the PI3K pathway 
(PIK3CA, AKT1), other integrins (ITGA6, ITGB1), stem cell markers (CD44, ITGA6) and 
the tetraspanin CD151.
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Table 1
Patient and tumor characteristics
N (% total)
Patient characteristics
  Age, mean (range years) 63 (range 39–84)
  Gender
    Female 88 (42%)
    Male 123 (58%)
  Smoking Status
    Total available 159
    Smoker 154 (97%)
    Never smoker 5 (3%)
  Residence
    Appalachian 145 (69%)
    Non-Appalachian 59 (28%)
    Out of state 7 (3%)
  Vital Status
    Alive 89 (42%)
    Deceased 122 (58%)
Tumor characteristics
  Histology
    Adenocarcinoma 81 (38%)
    Squamous cell carcinoma 99 (47%)
    Other 31 (15%)
  Differentiation
    Well 12 (6%)
    Moderate 87 (41%)
    Poor 112 (53%)
  AJCC Stage
    I 108 (51%)
    II 37 (18%)
    III 44 (21%)
    IV 13 (6%)
    Unknown 9 (4%)
Total 211
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Table 2
Integrin β4 expression in NSCLC by histologic subtype.
Integrin β4 High Integrin β4 Low
Total 101/211 (48%) 110/211 (52%)
Histologic Type:
Squamous cell carcinoma 77/99 (78%) 22/99 (22%)
Adenocarcinoma 11/81 (14%) 70/81 (86%)
Other histologic types:
Poorly differentiated 5/12 (42%) 7/12 (58%)
Adenosquamous 7/12 (58%) 5/12 (42%)
Mixed histology 1/2 (50%) 1/2 (50%)
Large cell neuroendocrine 0/2 (0%) 2/2 (100%)
Pleomorphic carcinoma 0/1 (0%) 1/1 (100%)
Giant cell carcinoma 0/1 (0%) 1/1 (100%)
Sarcomatoid carcinoma 0/1 (0%) 1/1 (100%)
Hum Pathol. Author manuscript; available in PMC 2017 August 01.
